βTrCP-dependent degradation of CDC25B phosphatase at the metaphase-anaphase transition is a pre-requisite for correct mitotic exit

Cell Cycle

Volumn 9, Issue 21, 2010, Pages 4338-4350

  Thomas, Yann ^a   Coux, Olivier ^a   Baldin, Véronique ^a  

^a Centre National de la Recherche Scientifique   (France)

Author keywords

CDC25B phosphatase; Mitosis exit; TrCP

Indexed keywords

BETA TRCP PROTEIN; CDC25B PHOSPHATASE; F BOX PROTEIN; PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG;

ANAPHASE; ANIMAL CELL; ARTICLE; CARCINOGENESIS; CHROMOSOME SEGREGATION; CONTROLLED STUDY; ENZYME DEGRADATION; GENOMIC INSTABILITY; MAMMAL CELL; METAPHASE; MITOSIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN METABOLISM;

MAMMALIA;

EID: 78349278016     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.21.13593     Document Type: Article

References (65)

1. Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci 2005; 30:630-41.
2. Pavletich NP. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators and Cip and INK4 inhibitors. J Mol Biol 1999; 287:821-8.
3. Pines J. Cyclins and cyclin-dependent kinases: a biochemical view. Biochem J 1995; 308:697-711.
4. Minshull J, Pines J, Golsteyn R, Standart N, Mackie S, Colman A, et al. The role of cyclin synthesis, modification and destruction in the control of cell division. J Cell Sci Suppl 1989; 12:77-97.
5. Baldin V, Cans C, Superti-Furga G, Ducommun B. Alternative splicing of the human CDC25B tyrosine phosphatase. Possible implications for growth control? Oncogene 1997; 14:2485-95.
6. Forrest AR, McCormack AK, DeSouza CP, Sinnamon JM, Tonks ID, Hayward NK, et al. Multiple splicing variants of cdc25B regulate G2/M progression. Biochem Biophys Res Commun 1999; 260:510-5.
7. Bureik M, Rief N, Drescher R, Jungbluth A, Montenarh M, Wagner P. An additional transcript of the cdc25C gene from A431 cells encodes a functional protein. Int J Oncol 2000; 17:1251-8.
8. Wegener S, Hampe W, Herrmann D, Schaller HC. Alternative splicing in the regulatory region of the human phosphatases CDC25A and CDC25C. Eur J Cell Biol 2000; 79:810-5.
9. Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer 2007; 7:495-507.
10. Garner-Hamrick PA, Fisher C. Antisense phosphorothioate oligonucleotides specifically downregulate cdc25B causing S-phase delay and persistent antiproliferative effects. Int J Cancer 1998; 76:720-8.
11. Blomberg I, Hoffmann I. Ectopic expression of Cdc25A accelerates the G(1)/S transition and leads to premature activation of cyclin E- and cyclin A-dependent kinases. Mol Cell Biol 1999; 19:6183-94.
12. Molinari M, Mercurio C, Dominguez J, Goubin F, Draetta GF. Human Cdc25 A inactivation in response to S phase inhibition and its role in preventing premature mitosis. EMBO Rep 2000; 1:71-9.
13. Turowski P, Franckhauser C, Morris MC, Vaglio P, Fernandez A, Lamb NJ. Functional cdc25C dual-specificity phosphatase is required for S-phase entry in human cells. Mol Biol Cell 2003; 14:2984-98.
14. Lindqvist A, Kallstrom H, Lundgren A, Barsoum E, Rosenthal CK. Cdc25B cooperates with Cdc25A to induce mitosis but has a unique role in activating cyclin B1-Cdk1 at the centrosome. J Cell Biol 2005; 171:35-45. (Pubitemid 41434600)
15. 2/M phase transition in human cells. J Cell Sci 1998; 111:2445-53.
16. Karlsson C, Katich S, Hagting A, Hoffmann I, Pines J. Cdc25B and Cdc25C differ markedly in their properties as initiators of mitosis. The Journal of cell biology 1999; 146:573-84.
17. Baldin V, Pelpel K, Cazales M, Cans C, Ducommun B. Nuclear localization of CDC25B1 and serine 146 integrity are required for induction of mitosis. J Biol Chem 2002; 277:35176-82.
18. Gabrielli BG, De Souza CP, Tonks ID, Clark JM, Hayward NK, Ellem KA. Cytoplasmic accumulation of cdc25B phosphatase in mitosis triggers centrosomal microtubule nucleation in HeLa cells. J Cell Sci 1996; 109:1081-93.
19. De Souza CP, Ellem KA, Gabrielli BG. Centrosomal and cytoplasmic Cdc2/cyclin B1 activation precedes nuclear mitotic events. Exp Cell Res 2000; 257:11-21.
20. 2/M transition and is inhibited by DNA damage. Cell Cycle 2005; 4:1233-8.
21. Theis-Febvre N, Filhol O, Froment C, Cazales M, Cochet C, Monsarrat B, et al. Protein kinase CK2 regulates CDC25B phosphatase activity. Oncogene 2003; 22:220-32.
22. Dutertre S, Cazales M, Quaranta M, Froment C, Trabut V, Dozier C, et al. Phosphorylation of CDC25B by Aurora-A at the centrosome contributes to the G2-M transition. J Cell Sci 2004; 117:2523-31. (Pubitemid 38877848)
23. Lobjois V, Jullien D, Bouche JP, Ducommun B. The polo-like kinase 1 regulates CDC25B-dependent mitosis entry. Biochim Biophys Acta 2009; 1793:462-8.
24. Davezac N, Baldin V, Blot J, Ducommun B, Tassan JP. Human pEg3 kinase associates with and phosphorylates CDC25B phosphatase: a potential role for pEg3 in cell cycle regulation. Oncogene 2002; 21:7630-41.
25. Baldin V, Theis-Febvre N, Benne C, Froment C, Cazales M, Burlet-Schiltz O, et al. PKB/Akt phosphorylates the CDC25B phosphatase and regulates its intracellular localisation. Biol Cell 2003; 95:547-54.
26. Schmitt E, Boutros R, Froment C, Monsarrat B, Ducommun B, Dozier C. CHK1 phosphorylates CDC25B during the cell cycle in the absence of DNA damage. J Cell Sci 2006; 119:4269-75. (Pubitemid 44774033)
27. Loffler H, Rebacz B, Ho AD, Lukas J, Bartek J, Kramer A. Chk1-dependent regulation of Cdc25B functions to coordinate mitotic events. Cell Cycle 2006; 5:2543-7.
28. Lemaire M, Froment C, Boutros R, Mondesert O, Nebreda AR, Monsarrat B, et al. CDC25B phosphorylation by p38 and MK-2. Cell Cycle 2006; 5:1649-53.
29. Baldin V, Cans C, Knibiehler M, Ducommun B. Phosphorylation of human CDC25B phosphatase by CDK1-cyclin A triggers its proteasome-dependent degradation. J Biol Chem 1997; 272:32731-4.
30. 2 phase cell cycle checkpoint blocks cdc25-dependent progression into mitosis. Oncogene 1997; 15:749-58.
31. Nishijima H, Nishitani H, Seki T, Nishimoto T. A dual-specificity phosphatase Cdc25B is an unstable protein and triggers p34(cdc2)/cyclin B activation in hamster BHK21 cells arrested with hydroxyurea. J Cell Biol 1997; 138:1105-16. (Pubitemid 27386459)
32. Kanemori Y, Uto K, Sagata N. Beta-TrCP recognizes a previously undescribed nonphosphorylated destruction motif in Cdc25A and Cdc25B phosphatases. Proceedings of the National Academy of Sciences of the United States of America 2005; 102:6279-84.
33. Kieffer I, Lorenzo C, Dozier C, Schmitt E, Ducommun B. Differential mitotic degradation of the CDC25B phosphatase variants. Oncogene 2007; 26:7847-58.
34. Galaktionov K, Lee AK, Eckstein J, Draetta G, Meckler J, Loda M, et al. CDC25 phosphatases as potential human oncogenes. Science 1995; 269:1575-7.
35. Broggini M, Buraggi G, Brenna A, Riva L, Codegoni AM, Torri V, et al. Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients. Anticancer Res 2000; 20:4835-40. (Pubitemid 32127739)
36. Takemasa I, Yamamoto H, Sekimoto M, Ohue M, Noura S, Miyake Y, et al. Overexpression of CDC25B phosphatase as a novel marker of poor prognosis of human colorectal carcinoma. Cancer Res 2000; 60:3043-50.
37. Ngan ES, Hashimoto Y, Ma ZQ, Tsai MJ, Tsai SY. Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer. Oncogene 2003; 22:734-9.
38. Ito Y, Yoshida H, Matsuzuka F, Matsuura N, Nakamura Y, Nakamine H, et al. Cdc25A and cdc25B expression in malignant lymphoma of the thyroid: correlation with histological subtypes and cell proliferation. Int J Mol Med 2004; 13:431-5.
39. Yan X, Chua MS, He J, So SK. Small interfering RNA targeting CDC25B inhibits liver tumor growth in vitro and in vivo. Mol Cancer 2008; 7:19. (Pubitemid 351472330)
40. Kristjansdottir K, Rudolph J. Cdc25 phosphatases and cancer. Chem Biol 2004; 11:1043-51.
41. Galaktionov K, Chen X, Beach D. Cdc25 cell cycle phosphatase as a target of c-myc. Nature 1996; 382:511-7.
42. + gene occurs in humans and is highly expressed in some cancer cells. New Biol 1991; 3:959-68.
43. Fuchs SY, Spiegelman VS, Kumar KG. The many faces of beta-TrCP E3 ubiquitin ligases: reflections in the magic mirror of cancer. Oncogene 2004; 23:2028-36.
44. Guardavaccaro D, Kudo Y, Boulaire J, Barchi M, Busino L, Donzelli M, et al. Control of meiotic and mitotic progression by the F box protein beta-Trcp1 in vivo. Dev cell 2003; 4:799-812.
45. Bugler B, Schmitt E, Aressy B, Ducommun B. Unscheduled expression of CDC25B in S-phase leads to replicative stress and DNA damage. Mol Cancer 2010; 9:29.
46. Watanabe N, Arai H, Nishihara Y, Taniguchi M, Hunter T, Osada H. M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFbeta-TrCP. Proceedings of the National Academy of Sciences of the United States of America 2004; 101:4419-24. (Pubitemid 38437427)
47. Mailand N, Bekker-Jensen S, Bartek J, Lukas J. Destruction of Claspin by SCFbetaTrCP restrains Chk1 activation and facilitates recovery from genotoxic stress. Mol Cell 2006; 23:307-18.
48. Peschiaroli A, Dorrello NV, Guardavaccaro D, Venere M, Halazonetis T, Sherman NE, et al. SCFbetaTrCP-mediated degradation of Claspin regulates recovery from the DNA replication checkpoint response. Mol Cell 2006; 23:319-29.
49. Seki A, Coppinger JA, Du H, Jang CY, Yates JR, 3rd, Fang G. Plk1- and beta-TrCP-dependent degradation of Bora controls mitotic progression. J Cell Biol 2008; 181:65-78.
50. Besnard-Guerin C, Belaidouni N, Lassot I, Segeral E, Jobart A, Marchal C, et al. HIV-1 Vpu sequesters beta-transducin repeat-containing protein (betaTrCP) in the cytoplasm and provokes the accumulation of beta-catenin and other SCFbetaTrCP substrates. J Biol Chem 2004; 279:788-95.
51. waf1/cip1 proteasomal turnover independently of ubiquitylation. EMBO J 2003; 22:6365-77.
52. Sdek P, Ying H, Chang DL, Qiu W, Zheng H, Touitou R, et al. MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. Mol Cell 2005; 20:699-708. (Pubitemid 41740692)
53. Lee H, Zeng SX, Lu H. UV Induces p21 rapid turnover independently of ubiquitin and Skp2. J Biol Chem 2006; 281:26876-83.
54. 1 and early S phases independently of, but in cooperation with, MDM2. Mol Cell Biol 2008; 28:1218-29.
55. Jariel-Encontre I, Bossis G, Piechaczyk M. Ubiquitinindependent degradation of proteins by the proteasome. Biochim Biophys Acta 2008; 1786:153-77.
56. Bendjennat M, Boulaire J, Jascur T, Brickner H, Barbier V, Sarasin A, et al. UV irradiation triggers ubiquitin-dependent degradation of p21(WAF1) to promote DNA repair. Cell 2003; 114:599-610.
57. Chen X, Barton LF, Chi Y, Clurman BE, Roberts JM. Ubiquitin-independent degradation of cell cycle inhibitors by the REGgamma proteasome. Mol Cell 2007; 26:843-52. (Pubitemid 46921008)
58. Li X, Amazit L, Long W, Lonard DM, Monaco JJ, O'Malley BW. Ubiquitin- and ATP-independent proteolytic turnover of p21 by the REGgamma-proteasome pathway. Mol Cell 2007; 26:831-42. (Pubitemid 46921009)
59. Donzelli M, Squatrito M, Ganoth D, Hershko A, Pagano M, Draetta GF. Dual mode of degradation of Cdc25 A phosphatase. EMBO J 2002; 21:4875-84.
60. Tucker JD, Preston RJ. Chromosome aberrations, micronuclei, aneuploidy, sister chromatid exchanges and cancer risk assessment. Mutat Res 1996; 365:147-59.
61. Davezac N, Baldin V, Gabrielli B, Forrest A, Theis-Febvre N, Yashida M, et al. Regulation of CDC25B phosphatases subcellular localization. Oncogene 2000; 19:2179-85.
62. Tempe D, Casas M, Karaz S, Blanchet-Tournier MF, Concordet JP. Multisite protein kinase A and glycogen synthase kinase 3beta phosphorylation leads to Gli3 ubiquitination by SCFbetaTrCP. Mol Cell Biol 2006; 26:4316-26.
63. Baldin V, Militello M, Thomas Y, Doucet C, Fic W, Boireau S, et al. A novel role for PA28gamma-proteasome in nuclear speckle organization and SR protein trafficking. Mol Biol Cell 2008; 19:1706-16. (Pubitemid 351805122)
64. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 1993; 7:812-21. (Pubitemid 23163585)
65. Cans C, Sert V, De Rycke J, Baldin V, Ducommun B. Use of CDC2 from etoposide-treated cells as substrate to assay CDC25 phosphatase activity. Anticancer Res 1999; 19:1241-4.